Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

UCB And Biogen Announced Positive Topline Results Phase 3 Study of Dapirolizumab Pegol for Systemic Lupus Erythematosus

September 24, 2024 0

UCB and Biogen Positive Results UCB (Euronext Brussels: UCB) and Biogen Inc. (BIIB) announced positive . . . This …

Sanofi Product Sarclisa Approved in the US as the First anti-CD38 Therapy

September 23, 2024 0

Sanofi Approval The United States FDA approved Sanofi (SNY) product Sarclisa (isatuximab) in combination with bortezomib, …

Aligos Therapeutics Announces Positive Topline Results from Phase 2A Herald Study of ALG-055009 for the Treatment of MASH

September 20, 2024 0

Aligos Therapeutics in the NEWS Yesterday, Sept. 19, 2024, Aligos Therapeutics (ALGS) - a small clinical-stage …

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis

September 19, 2024 0

AstaZeneca Fasenra Approval AstraZeneca (AZN) product Fasenra (bevacizumab) has been approved in the US for the treatment …

The U.S. FDA Approves Novartis’ Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024 0

Novartis FDA Approval Yesterday, September 17, 2024, Novartis (NVS) announced that the United States FDA has …

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024 0

AstraZeneca Imfinzi + Imjudo Updated results from the HIMALAYA Phase III trial have demonstrated that AstraZeneca …

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024 0

Halozyme Therapeutics in the NEWS Halozyme Therapeutics, Inc. (HALO) announced that Roche received U.S. Food and …

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024 0

Johnson & Johnson FDA Approval Yesterday, September 11, 2024, Johnson & Johnson (JNJ) announced that the …

Travere Therapeutics Announces Full FDA Approval of FILSPARI®

September 11, 2024 0

Travere Therapeutics Approval Travere Therapeutics, Inc., (TVTX) announced that the U.S. FDA has granted full approval to …

Gilead Therapeutics and Genesis Therapeutics Announced Strategic Collaboration to Discover and Develop Novel Therapies

September 10, 2024 0

Gilead Sciences and Genesis Therapeutics Gilead Sciences (GILD) and Genesis Therapeutics, Inc. announced today that the …

Regenxbio Announces Positive Results of its Product RGX-121 for Hunter Syndrome

September 5, 2024 0

Regenxbio Positive Results Regenxbio (RGNX) announced positive results from the Phase I/II/III CAMPSIITE® trial of RGX-121 …

Jeune Aesthetics: Reversing the Biology of Aging Skin to Meet the Growing Demand

September 4, 2024 0

Jeune Aesthetics Announces Phase 1 Positive Interim Safety and Efficacy Results for KB301 On August 28, …

Merck Discontinues Two Late-Stage Keytruda Trials and Other Important Information

August 29, 2024 0

Merck Updates Merck (MRK) provided updates on two Phase 3 trials, KEYNOTE-867 and KEYNOTE-630, stating that …

Good News for Vertex Pharmaceuticals and for Crispr Therapeutics

August 27, 2024 0

Vertex Announces CASGEVY™ Reimbursement Agreement with NHS England Vertex Pharmaceuticals (VRTX) announced a reimbursement agreement with …

Prohost Letter #461 ~ Preventing HIV Infection and Treating Primary Biliary Cholangitis

August 21, 2024 0

Prohost Letter #461 Preventing HIV Infection and Treating Primary Biliary Cholangitis Gilead Sciences Gilead Sciences’ (GILD) …

Gilead Sciences Livdelzi Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA

August 15, 2024 0

Gilead Sciences Approval Gilead Sciences (GILD) today announced that the U.S. FDA has granted accelerated approval …

Galderma Receives U.S. FDA Approval for Nemluvio® for Adult Patients with Prurigo Nodularis

August 13, 2024 0

Galderma: FDA Approval for Nemluvio® Today, August 13, 2024, Galderma (GALD.SW) announced that the U.S. FDA …

Cytokinetics Reports Management Update and Q2 2024 Financial Results

August 12, 2024 0

Cytokinetics Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing, and commercializing muscle …

Akero Therapeutics Reports Q2 2024 Financial Results and Business Update

August 9, 2024 0

Akero Therapeutics Q2 and Business Update Akero Therapeutics (AKRO) reported second-quarter financial results for the period …

Exelixis Announces Q2 2024 Financial Results and Provides Corporate Update

August 7, 2024 0

Exelixis Q2 Results and Corporate Update Yesterday, Aug. 6, 2024, Exelixis, (EXEL) reported financial results for …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

UCB And Biogen Announced Positive Topline Results Phase 3 Study of Dapirolizumab Pegol for Systemic Lupus Erythematosus

Sanofi Product Sarclisa Approved in the US as the First anti-CD38 Therapy

Aligos Therapeutics Announces Positive Topline Results from Phase 2A Herald Study of ALG-055009 for the Treatment of MASH

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis

The U.S. FDA Approves Novartis’ Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

Travere Therapeutics Announces Full FDA Approval of FILSPARI®

Gilead Therapeutics and Genesis Therapeutics Announced Strategic Collaboration to Discover and Develop Novel Therapies

Regenxbio Announces Positive Results of its Product RGX-121 for Hunter Syndrome

Jeune Aesthetics: Reversing the Biology of Aging Skin to Meet the Growing Demand

Merck Discontinues Two Late-Stage Keytruda Trials and Other Important Information

Good News for Vertex Pharmaceuticals and for Crispr Therapeutics

Prohost Letter #461 ~ Preventing HIV Infection and Treating Primary Biliary Cholangitis

Gilead Sciences Livdelzi Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA

Galderma Receives U.S. FDA Approval for Nemluvio® for Adult Patients with Prurigo Nodularis

Cytokinetics Reports Management Update and Q2 2024 Financial Results

Akero Therapeutics Reports Q2 2024 Financial Results and Business Update

Exelixis Announces Q2 2024 Financial Results and Provides Corporate Update